Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-27T03:02:15.814Z Has data issue: false hasContentIssue false
  • English
  • Français

Antidepressant treatment response of postpartum depression: Clinical and genetic factors

Published online by Cambridge University Press:  16 April 2020

R. Martin-Santos ,
E. Gelabert ,
A. Plaza ,
P. Navarro ,
R. Navines ,
C. Ascaso ,
C. Garcia ,
M. Gratacos ,
X. Estivill  and
L.L. Garcia Esteve
R. Martin-Santos
Affiliation:
Pharmacology Research Unit, Institut Municipal d'Investigació Mèdica (IMIM), Barcelona, Spain
E. Gelabert
Affiliation:
Pharmacology Research Unit, Institut Municipal d'Investigació Mèdica (IMIM), Barcelona, Spain
A. Plaza
Affiliation:
Perinal Psychiatric and Gender Research Unit, Hospital Clinic and Public Health Department, UB, Barcelona, Spain
P. Navarro
Affiliation:
Perinal Psychiatric and Gender Research Unit, Hospital Clinic and Public Health Department, UB, Barcelona, Spain
R. Navines
Affiliation:
Pharmacology Research Unit, Institut Municipal d'Investigació Mèdica (IMIM), Barcelona, Spain
C. Ascaso
Affiliation:
Perinal Psychiatric and Gender Research Unit, Hospital Clinic and Public Health Department, UB, Barcelona, Spain
C. Garcia
Affiliation:
Genes and Disease Program, Center of Genomic Regulation (CRG), Barcelona, Spain
M. Gratacos
Affiliation:
Genes and Disease Program, Center of Genomic Regulation (CRG), Barcelona, Spain
X. Estivill
Affiliation:
Genes and Disease Program, Center of Genomic Regulation (CRG), Barcelona, Spain
L.L. Garcia Esteve
Affiliation:
Perinal Psychiatric and Gender Research Unit, Hospital Clinic and Public Health Department, UB, Barcelona, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Pharmacologic treatment of mood disorders reduces morbidity of depressive disorders and improves quality of life. Not all patients benefit from treatment. Close to 30% to 40% does not improve enough to the first antidepressant they receive. Many factors are assumed to contribute to this. In the last years it has been studied genetic factors predisposing to drug response or side effects in mood disorders. The efficacy of antidepressant action has been associated to several polymorphisms located in candidate genes related to serotonin pathway.

The prevalence of major depression occurring in the postpartum (PPD) is estimated at 4%-6% and results in considerable morbidity for women, their infants and families. The period of higher risk of PPD appear to occur close to the time of birth between 8 to 24 weeks. It seems that PPD episode is severe and longer than episodes outside this period of life. Initial results showed that women with PPD experienced fewer episodes during illness course compared to non postpartum women and less comorbidity with personality disorders.

We presented preliminary socio-demographic, clinical and genetic data (5-HTTLPPR polymorphism) of a case control studied of women with PPD naturalist treated with SSRI visited at the Perinatal Psychiatric Unit. All women were diagnosed by a DSM-IV structured interview and assessed for personality traits. Therapeutical SSRI response was evaluated by the Edinburgh Postnatal Depression Scale and the Hamilton rating Scale for depression at baseline, 8 weeks and 24 weeks of treatment.

This project is funded in part by Marató-TV3, GO3/184, and FIS-05/2565.

Type
S26. Symposium: Advances in Treatment of Perinatal Mental Disorders
Information
European Psychiatry , Volume 22 , Issue S1: 15th AEP Congress - Abstract book - 15th AEP Congress , March 2007 , pp. S43
Copyright
Copyright © European Psychiatric Association 2007
Submit a response

Comments

No Comments have been published for this article.